EMYRIA LIMITED — Capital/Financing Update 2021

Feb 4, 2021

ASX Announcement

05/02/2021

Emyria wins digital health monitoring grant with UWA

Highlights:

• Emyria’s remote monitoring service - Openly - will provide advanced digital and mental health monitoring as part of successful grant

• Total grant award totals $880,000, of which Emyria expects to receive between $320,000 and $400,000 over 2 years

• Aims of the grant are to boost digital health infrastructure in WA and will involve monitoring the vital signs and mental health of at-risk individuals and confirmed COVID-19 individuals

• Key researchers and collaborators involved include:

  • Professor Bruce Robinson - Principal investigator, respiratory physician and scientist with the Institute for Respiratory Health

  • Dr Ben Scalley - Head of WA’s Public Health Emergency Operations Centre and;

  • ○ Professor Sean Hood - Head of clinical psychopharmacology with UWA’s Division of Psychiatry

Emyria Limited (ASX: EMD) (Emyria or the Company) is pleased to announce that their advanced remote monitoring digital health platform and service - Openly - will play a central role in a recently awarded grant from Western Australia’s Future Health Research and Innovation Fund. [1]

The successful grant is titled “An advanced digital monitoring and engagement platform for at-risk and confirmed COVID-19 individuals” and is intended to boost Western Australia’s digital health infrastructure and capacity to manage future health challenges like COVID-19.

The aims of the grant are to evaluate the utility of advanced digital health monitoring in vulnerable patient populations, to improve engagement amongst aged and ethnic populations and to improve mental health evaluation and monitoring for those under remote care.

Emyria will take a leadership role in the grant and will lead a multidisciplinary collaboration involving the state’s major health services and universities. The grant will also extend Emyria’s collaboration with Mt Sinai, New York. (See ASX announcement 17 Sep 2020).

1

==> picture [137 x 40] intentionally omitted <==

Openly supports digital health and wellness screening using smart mobile devices and backed by Emyria’s clinical team. Openly was initially developed to assist with contactless remote COVID-19 screening and management. On 15 September 2020, was registered as a Class 1 medical device with the Australian Therapeutic Goods Administration (TGA). (See ASX announcement 15 Sep 2020)

Openly helps collect real-world clinical information from individuals remotely such as heart rate and heart rate variability. This information is presented to a clinical team who can act on that information. When vital signs such as heart rate variability change from baseline it can signal early infection or mental distress.

Emyria’s Managing Director, Dr Michael Winlo, said: “It’s very pleasing to see our unique contactless remote monitoring platform - Openly - recognised through this competitive grant process. Emyria’s unique digital health technology and clinical team will be playing a major role in improving how we monitor the clinical and mental wellbeing of vulnerable populations in WA.

Emyria has been developing digital health and remote monitoring technologies to improve the care of patients with unmet needs. We focus on the care of complex patients and those with mental health concerns.

Openly - the core technology of this grant - will also support and monitor patients during our upcoming clinical trials. These pivotal studies will support the registration of our leading drug candidate EMD-003 - targeting unmet needs in psychological distress and the symptoms of anxiety, depression and stress.”

More details on the grant are expected to be announced in future updates.

This announcement has been approved and authorised for release by the Board of Emyria Limited.

For further information:

Dr Michael Winlo Lexi O’Halloran Managing Director Media/Investor Relations (08) 6559 2800 + 61 (0) 404 577 076 mwinlo@emyria.com lexi@janemorganmanagement.com.au

Andrew Williams Media Relations +61 (0) 412 614 125 andreww@proflemedia.com.au

Sources:

1. https://fhrifund.health.wa.gov.au/Funding/Current-opportunities/FHRI-Focus-Grants---COVID-19/FHRI-F ocus-Grants---COVID-19-Recipients

2

==> picture [137 x 40] intentionally omitted <==

About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services ( Emerald Clinics - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Emyria’s first drug development program, EMD-003 is targeting unmet needs in mental health. Specifically psychological distress and the symptoms of anxiety, depression and stress.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

3